Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock（LXEO）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · LXEO · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
26
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Lexeo Therapeutics, Inc. Common Stock内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
LXEO 季度内部人买卖趋势
LXEO 内幕交易卖出 · LXEO 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · LXEO CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
LXEO 高管卖出股份 · LXEO 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 18, 2026 | Otero Jose Manuel COO | Sale | 1,302 | $7K | Form 4 |
| May 18, 2026 | Townsend Richard Nolan CEO · Director | Sale | 3,342 | $17K | Form 4 |
| Apr 6, 2026 | Townsend Richard Nolan CEO · Director | Sale | 55,000 | $313K | Form 4 |
| Mar 13, 2026 | Townsend Richard Nolan CEO · Director | Award | 2,623 | $7K | Form 4 |
| Mar 13, 2026 | Otero Jose Manuel COO | Award | 5,930 | $16K | Form 4 |
| Feb 18, 2026 | Otero Jose Manuel COO | Sale | 3,016 | $19K | Form 4 |
| Feb 18, 2026 | Townsend Richard Nolan CEO · Director | Sale | 10,173 | $65K | Form 4 |
| Feb 13, 2026 | Bhalla Narinder Pal Chief Medical Officer | Award | 49,500 | — | Form 4 |
| Feb 4, 2026 | Townsend Richard Nolan CEO · Director | Award | 161,665 | — | Form 4 |
| Feb 4, 2026 | Otero Jose Manuel COO | Award | 65,000 | — | Form 4 |
| Feb 4, 2026 | Tamayo Louis Edward CFO | Award | 44,665 | — | Form 4 |
| Nov 18, 2025 | Townsend Richard Nolan CEO · Director | Sale | 1,127 | $10K | Form 4 |
| Nov 18, 2025 | Adler Eric Chief Medical Officer | Sale | 615 | $6K | Form 4 |
| Nov 18, 2025 | See Tai Sandi Chief Development Officer | Sale | 386 | $4K | Form 4 |
| Nov 18, 2025 | Robertson Jenny Chief Legal Officer | Sale | 549 | $5K | Form 4 |
| Aug 18, 2025 | Otero Jose Manuel Chief Technical Officer | Sale | 721 | $7K | Form 4 |
| Oct 15, 2025 | See Tai Sandi Chief Development Officer | Award | 10,890 | — | Form 4 |
| Oct 17, 2025 | See Tai Sandi Chief Development Officer | Sale | 3,844 | $34K | Form 4 |
| Oct 17, 2025 | See Tai Sandi Chief Development Officer | Sale | 44 | $421 | Form 4 |
| Oct 15, 2025 | Robertson Jenny Chief Legal Officer | Award | 9,900 | — | Form 4 |
| Oct 17, 2025 | Robertson Jenny Chief Legal Officer | Sale | 3,486 | $31K | Form 4 |
| Oct 17, 2025 | Robertson Jenny Chief Legal Officer | Sale | 40 | $382 | Form 4 |
| Oct 15, 2025 | Otero Jose Manuel Chief Technical Officer | Award | 5,940 | — | Form 4 |
| Oct 17, 2025 | Otero Jose Manuel Chief Technical Officer | Sale | 2,091 | $19K | Form 4 |
| Oct 17, 2025 | Otero Jose Manuel Chief Technical Officer | Sale | 24 | $229 | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 LXEO 内幕交易
LXEO 内幕交易
Lexeo Therapeutics, Inc. Common Stock（LXEO）内幕交易数据来源于公司内部人（包括Townsend Richard Nolan (CEO · Director), Otero Jose Manuel (COO), Adler Eric (Chief Medical Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。LXEO内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Lexeo Therapeutics, Inc. Common Stock机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
LXEO 内幕交易 · 5个问题Lexeo Therapeutics, Inc. Common Stock（LXEO）的内部人包括高管和董事，如Townsend Richard Nolan (CEO · Director), Otero Jose Manuel (COO), Adler Eric (Chief Medical Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026